Connect with us
European Gaming Congress 2024

Artificial Intelligence

Global Orotic Aciduria Market Size Is Forecasted to Reach USD 507.96 Million by 2030, Growing at a 5.10% CAGR

Published

on

Washington, DC, June 15, 2023 (GLOBE NEWSWIRE) — Zion Market Research has published a new research report titled “Orotic Aciduria Market By Drug Type (Uridine Monophosphate, Cytidine Monophosphate, And Others), By Type (Type II And Type I), And By Region – Global And Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, And Forecasts 2023 – 2030” in its research database.

“According to the latest research study, the demand of global Orotic Aciduria Market size & share in terms of revenue was valued at USD 341.22 million in 2022 and it is expected to surpass around USD 507.96 million mark by 2030, growing at a compound annual growth rate (CAGR) of approximately 5.10% during the forecast period 2023 to 2030.”

What is Orotic Aciduria? How big is the Orotic Aciduria Industry?

Report Overview:

The global orotic aciduria market size was worth around USD 341.22 million in 2022 and is predicted to grow to around USD 507.96 million by 2030 with a compound annual growth rate (CAGR) of roughly 5.10% between 2023 and 2030.

Advertisement
Stake.com

The orotic aciduria market refers to the economic landscape and scenarios surrounding the diagnosis, treatment, and management of orotic aciduria. It is a genetic disorder that is characterized by impaired synthesis of pyrimidine. The industry encompasses various stakeholders and includes pharmaceutical companies, research organizations, healthcare providers, regulatory authorities, patient advocacy groups, and patients themselves. It deals with the development and availability of diagnostic tests, therapeutic interventions, and supportive care measures specifically designed for individuals with orotic aciduria. It is noteworthy, that as of 2023, there is a very small set of patients detected with this condition and hence there is a significant lack of large-scale research and trials surrounding the condition.

Get a Free Sample PDF of this Research Report for more Insights with a Table of Content, Research Methodology, and Graphs – https://www.zionmarketresearch.com/sample/orotic-aciduria-market

(A free sample of this report is available upon request; please contact us for more information.)

Our Free Sample Report Consists of the Following:

  • Introduction, Overview, and in-depth industry analysis are all included in the 2023 updated report.
  • The COVID-19 Pandemic Outbreak Impact Analysis is included in the package
  • About 216+ Pages Research Report (Including Recent Research)
  • Provide detailed chapter-by-chapter guidance on Request
  • Updated Regional Analysis with Graphical Representation of Size, Share, and Trends for the Year 2023
  • Includes Tables and figures have been updated
  • The most recent version of the report includes the Top Market Players, their Business Strategies, Sales Volume, and Revenue Analysis
  • Zion Market Research research methodology

(Please note that the sample of this report has been modified to include the COVID-19 impact study prior to delivery.)

Global Orotic Aciduria Market: Growth Factors

Advertisement
Stake.com

The global orotic aciduria market is projected to grow owing to the rising interest of the research organizations especially toward rare conditions, as a main segment of study and orotic aciduria automatically becomes a part of this group. Large pharmaceutical companies with the aid of research groups are focusing on studying several underlying conditions that cause the onset of such conditions. They are also diverting resources toward improving diagnostic tools and educating the healthcare community about the several classes of rare genetic disorders and effective ways of diagnosing them.

In addition to this, such events and activities have received sufficient government assistance in terms of funds, grants, and incentives. This has led to higher growth in the orotic aciduria industry. In some countries, orphan drug designations and incentives are provided to encourage pharmaceutical companies to invest in rare disease therapies. A crucial role is played by advocacy organizations and patient support groups in educating the general public about issues that impact their health. In recent times, these groups have undertaken massive large-scale drives to create public awareness and such efforts are likely to contribute to industry growth.

The global orotic aciduria industry also faces certain growth restrictions with the primary being lack of a sufficient pool of patients to accurately conclude important aspects of the condition. These criteria include the cause of the disease, effective diagnosis, and efficient treatment programs. Additionally, since the disease is extremely rare, the cost of available treatment is high and hence can be undertaken by only a limited set of patients. Other factors such as lack of awareness, limited medical reimbursement, and complex regulatory pathway are also areas of great concern for the industry players.

The investments in personalized medicine approach may provide several growth opportunities while inaccurate diagnosis could challenge the market expansion.

Directly Purchase a copy of the report with TOC @ https://www.zionmarketresearch.com/buynow/su/orotic-aciduria-market

Advertisement
Stake.com

Report Scope

Report Attribute Details
Market Size in 2022 USD 341.22 million
Projected Market Size in 2030 USD 507.96 million
CAGR Growth Rate 5.10% CAGR
Base Year 2022
Forecast Years 2023-2030
Key Market Players Alexion Pharmaceuticals, Sanofi Genzyme, Roche Holding AG, Novartis AG, Pfizer Inc., Shire, BioMarin Pharmaceutical Inc., Vertex Pharmaceuticals Incorporated, Ultragenyx Pharmaceutical Inc., Horizon Therapeutics, CSL Behring, Sarepta Therapeutics, Regeneron Pharmaceuticals Inc., Moderna, Inc., bluebird bio, Sangamo Therapeutics, Amicus Therapeutics, Orchard Therapeutics, Abeona Therapeutics, PTC Therapeutics, Akcea Therapeutics, Catabasis Pharmaceuticals, Translate Bio, Homology Medicines, and Harmony Biosciences.
Key Segment By Drug Type, By Type, and By Region
Major Regions Covered North America, Europe, Asia Pacific, Latin America, and the Middle East &, Africa
Purchase Options Request customized purchase options to meet your research needs. Explore purchase options

Orotic Aciduria Market: Segmentation Analysis

The global orotic aciduria market is segmented based on drug type, type, and region.

Based on drug type, the global market segments are uridine monophosphate, cytidine monophosphate, and others. The industry registered the highest growth in the uridine monophosphate segment in 2022 since it is one of the most widely used drugs in treating the condition. It is typically administered as a therapeutic agent and it can bypass the deficiency of the enzyme uridine monophosphate synthase (UMPS). By providing this drug, medical professionals can restore the impaired pyrimidine synthesis pathway and aid in the reduction of orotic acid accumulation. However, it should be noted that the specific medication and treatment plan depends on the patient and the intensity of the disease. As of 2018, only 20 patients with this condition had been diagnosed.

Based on type, the orotic aciduria industry segments are type II and type I. Out of the two types, the latter is more common and it is also known as UMP synthase deficiency. The counterpart is referred to as hereditary orotic aciduria II or orotate phosphoribosyltransferase deficiency and this version is much rarer than type I. In type II, there is a deficiency in the enzyme orotate phosphoribosyltransferase (OPRT), which affects the conversion of orotic acid to orotidine-5′-monophosphate (OMP) in the pyrimidine synthesis pathway. As per the National Institute of Health, there are around 7000 rare conditions that are noted in the medical literature.

Advertisement
Stake.com

The global Orotic Aciduria market is segmented as follows:

By Drug Type

  • Uridine Monophosphate
  • Cytidine Monophosphate
  • Others

By Type

  • Type II
  • Type I

Browse the full “Orotic Aciduria Market By Drug Type (Uridine Monophosphate, Cytidine Monophosphate, And Others), By Type (Type II And Type I), And By Region – Global And Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, And Forecasts 2023 – 2030″– Report at https://www.zionmarketresearch.com/report/orotic-aciduria-market

Competitive Landscape

Some of the main competitors dominating the global Orotic Aciduria market include – 

  • Alexion Pharmaceuticals
  • Sanofi Genzyme
  • Roche Holding AG
  • Novartis AG
  • Pfizer Inc.
  • Shire
  • BioMarin Pharmaceutical Inc.
  • Vertex Pharmaceuticals Incorporated
  • Ultragenyx Pharmaceutical Inc.
  • Horizon Therapeutics
  • CSL Behring
  • Sarepta Therapeutics
  • Regeneron Pharmaceuticals Inc.
  • Moderna Inc.
  • bluebird bio
  • Sangamo Therapeutics
  • Amicus Therapeutics
  • Orchard Therapeutics
  • Abeona Therapeutics
  • PTC Therapeutics
  • Akcea Therapeutics
  • Catabasis Pharmaceuticals
  • Translate Bio
  • Homology Medicines
  • Harmony Biosciences.

 Key Insights from Primary Research:

  • According to the analysis shared by our research forecaster, the Orotic Aciduria market is likely to expand at a CAGR of around 5.10% during the forecast period (2023-2030).                                            
  • In terms of revenue, the Orotic Aciduria market size was valued at around US$ 341.22 million in 2022 and is projected to reach US$ 507.96 million by 2030.
  • The orotic aciduria market is projected to grow at a significant rate due to the growing awareness rate.
  • Based on drug type segmentation, uridine monophosphate was predicted to show maximum market share in the year 2022.
  • Based on type segmentation, type I was the leading segment in 2022.
  • On the basis of region, North America was the leading revenue generator in 2022.

Have Any Query? Ask Our Experts: https://www.zionmarketresearch.com/inquiry/orotic-aciduria-market

Key questions answered in this report:

Advertisement
Stake.com
  • What is the market size and growth rate forecast for Orotic Aciduria industry?
  • What are the main driving factors propelling the Orotic Aciduria Market forward?
  • What are the leading companies in the Orotic Aciduria Industry?
  • What segments does the Orotic Aciduria Market cover?
  • How can I receive a free copy of the Orotic Aciduria Market sample report and company profiles?

Key Offerings:

  • Market Size & Forecast by Revenue | 2023−2030
  • Market Dynamics – Leading Trends, Growth Drivers, Restraints, and Investment Opportunities
  • Market Segmentation – A detailed analysis By Drug Type, By Type, and By Region
  • Competitive Landscape – Top Key Vendors and Other Prominent Vendors

Request for Customization on this Report as per your requirements – https://www.zionmarketresearch.com/custom/7259

(We tailor your report to meet your specific research requirements. Inquire with our sales team about customising your report.)

Regional Analysis:

The global orotic aciduria market is expected to witness the highest growth in North America driven by the presence of robust medical infrastructure and research ecosystem. These nations are equipped with better diagnostic capabilities, access to specialized care, and ongoing research initiatives. Other factors such as better diagnostic capabilities, access to specialized care, and ongoing research initiatives.

Growth in Europe is projected to be led by regional and national initiatives supporting research, diagnosis, and treatment of rare diseases, including orotic aciduria. European Reference Networks (ERNs) facilitate collaboration among healthcare professionals across different countries. The European Medicines Agency (EMA) provides guidelines and incentives for orphan drug development. Access to specialized care, including metabolic centers, may vary across different European countries.

By Region

Advertisement
Stake.com
  • North America
    • U.S.
    • Canada
    • Rest of North America
  • Europe
    • France
    • UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Rest of Asia Pacific
  • The Middle East & Africa
    • Saudi Arabia
    • South Africa
    • Rest of the Middle East & Africa
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America

Recent Developments

  • In February 2023, the Center for Drug Evaluation and Research (CDER) announced the launch of the Accelerating Rare Disease Cures (ARC) Program which is expected to leverage the collective expertise of CDER
  • In August 2022, The Karnataka Government of India launched a new research and training unit focusing on rare diseases

To know an additional revised 2023 list of market players, request a brochure of the report: https://www.zionmarketresearch.com/requestbrochure/orotic-aciduria-market

Browse Other Related Research Reports from Zion Market Research:

Ultrasound (Cart/Trolley Based Ultrasound Devices and Compact Ultrasound Devices) Market By Technology, (2D, 3D, 4D Doppler and Other), By Application (Radiology, Cardiology, Urology, Gastroenterology, Gynecology and Others) – Global Industry Perspective, Comprehensive Analysis and Forecast, 2015 – 2021: https://www.zionmarketresearch.com/report/ultrasound-market

Respiratory Disease Testing (Imaging, Spirometry, Peak Flow, Blood Gas, Lung Volume, and other Tests) for Hospitals, Physician Offices and Clinical Laboratories Market: Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends and Forecast, 2015 – 2021: https://www.zionmarketresearch.com/report/respiratory-disease-testing-market

Veterinary Vaccine Market by Application (Livestock Vaccines and Companion Vaccines), by Technology Types (Attenuated Vaccines, DNA Vaccines, Inactivated Vaccines, Toxoid Vaccines and Recombinant Vaccines) – Global Industry Perspective, Comprehensive Analysis and Forecast, 2015 – 2021: https://www.zionmarketresearch.com/report/veterinary-vaccine-market

Cardiovascular Monitoring and Diagnostic Devices Market by Product Type (ECG systems, Holter Monitors, Event Monitors, Implantable loop recorders, and ECG Management Systems) ¬- Global Industry Perspective, Comprehensive Analysis and Forecast, 2015 – 2021: https://www.zionmarketresearch.com/report/cardiovascular-monitoring-diagnostic-devices-market

Advertisement
Stake.com

Artificial Organ Bank Market: by Product Type (Artificial Organ and Bionics) by Technology (Mechanical, Electronics) Global Industry Perspective, Comprehensive Analysis and Forecast, 2014 – 2022: https://www.zionmarketresearch.com/report/artificial-organ-bank-market

Veterinary Anti-Infectives Market by Species Type (Livestock and Companion), by Drug Class (Antimicrobial, Antiviral, Antifungal and Antiparasitic Agents), by Mode of Administration (Oral, Parenteral and Topical) and End-users (Veterinary Hospitals, Veterinary Clinics, Pharmacies and Others): Global Industry Perspective, Comprehensive Analysis and Forecast, 2016 – 2022: https://www.zionmarketresearch.com/report/veterinary-anti-infectives-market

Intraocular Lens Market, by Type (Monofocal IOLs and Premium IOLs); By Application (Cataract Surgery, Refractive Lens Exchange Surgery, and Trauma Surgery); By Material (Polymethylmethacrylate (PMMA), Silicon, Hydrophobic Acrylic, and Hydrogel); By End-User (Hospitals, Ambulatory Surgical Centers (ASCs), Ophthalmology Clinics, and Eye Research Institutes): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2022: https://www.zionmarketresearch.com/report/intraocular-lens-market

Scar Treatment Market by Product Type (Topical Products, Laser Treatment, Surface Treatment and Injectables), by Scar Type (Atrophic Scars, Hypertrophic and Keloid Scars, Contracture Scars, Stretch Marks) and by End Users for Hospitals, ASC’s, Clinics and Others: Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 – 2023: https://www.zionmarketresearch.com/report/scar-treatment-market

Batten Disease Treatment Market by Disease Type (Infantile, Late Infantile, Juvenile and Adult) and by Therapy Type includes Occupational Therapy and Physical Therapy: Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 – 2023: https://www.zionmarketresearch.com/report/batten-disease-treatment-market

Advertisement
Stake.com

Ophthalmic Viscosurgical Devices Market by Dispersive, Cohesive, Combined), By Application (Cataract Surgery, Vitreoretinal Surgery, Refractive Surgery, Keratoplasty), By End User (hospitals and eye specialty clinics): Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 – 2023: https://www.zionmarketresearch.com/report/ophthalmic-viscosurgical-devices-market

About Zion Market Research:

Zion Market Research is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Zion Market Research are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds.

Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.

Follow Us on LinkedIn: https://www.linkedin.com/company/zion-market-research/

Advertisement
Stake.com

Follow Us on Twitter: https://twitter.com/zion_research

Follow Us on Facebook: https://www.facebook.com/zionmarketresearch

Follow Us on Pinterest: https://www.pinterest.com/zionmarketresearch/

Follow Us on YouTube: https://youtu.be/Y0Yfi7N8zSs

Contact Us:

Advertisement
Stake.com

Rushikesh Dorge

USA: +1 347 690-0211

United Kingdom: +44 2032 894158

Japan: +81 50 5806 9039

India: +91 7768 006 007

Advertisement
Stake.com

Web: https://www.zionmarketresearch.com/

Blog: https://zmrblog.com/

Still, Looking for More Information? OR Want Data for Inclusion in Magazine, Case Study, or Media?

Email Directly Here with Detail Information: [email protected]

Advertisement
Stake.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

More than 150,000 money laundering accounts detected in APAC

Published

on

more-than-150,000-money-laundering-accounts-detected-in-apac

Region sees 108% increase in voice scams as fraudsters continue shift to mobile
MELBOURNE, Australia and MUMBAI, India, June 25, 2024 /PRNewswire/ — A new financial crime report out today details how criminal organizations in the APAC region now outsource the laundering of money stolen via scams to international syndicates specializing in this cleaning. BioCatch identified and helped APAC banks shut down more than 150,000 money mule accounts in 2023 and estimates exponentially more such accounts in use across the region.

“Where there are scams, there are mules,” BioCatch Director of Global Fraud Intelligence Tom Peacock said. “Criminal organizations use these mule accounts as intermediate stops between the victim’s bank account and the final account from which they plan to withdraw their stolen money. The mules we’ve identified almost certainly represent a tiny fraction of those actively laundering money in the region, with more cropping up every day. Financial institutions in APAC and around the world must do more to identify these mules, hamper their ability to open new accounts, and identify those legitimate accounts money launderers succeed in turning from good to bad.”
In this latest edition of its Digital Banking Fraud Trends in APAC report, BioCatch – which identifies and prevents fraud and financial crime in real time by analyzing as many as 3,000 different physical behavior patterns (mouse movements and typing speed, for example) and cognitive signals (hesitation, segmented typing, etc.) in search of anomalies – points to mobile malware as the greatest threat to banks in Southeast Asia in 2024.
“Whether through SMS-mining or illegal loan apps, we’ve seen an explosion in Android-based malware in the region,” Peacock said. “Malware developers continue to innovate, circumventing bank and Google Play Store defenses to harvest what they need from mobile devices to access digital banking accounts and then transfer away the victim’s funds to a money mule.”
There is reason for hope in fighting fraud in APAC, however. In Australia, the number of reported scam cases grew by 13% in 2023, but scam losses declined by $90 million.
“Nine out of the 10 largest Australian banks employ BioCatch solutions to protect their customers from fraud and financial crime by analyzing the behavior of the user behind every online banking session,” BioCatch APAC Vice President Richard Booth said. “Already in 2024, we see massive progress: Money lost to fraud in the country declined by 48% in the first quarter of this year compared to Q1 of 2023. It’s difficult to reach any conclusion other than that BioCatch has left Australian digital-banking customers far safer from fraud than they were before.”
Other key findings:
No desktop or laptop needed: BioCatch found as much as 70% of all reported frauds in APAC originated from mobile apps in 2023, an increase of 17% from the year before.Scams are everywhere: Across the region, the number of reported voice scams increased by 108% in 2023.Australia bucking all trends: In addition to seeing fraud losses actually decline, the nation also saw fewer fraud cases involving malware or Remote Administration Tools (RATs) in 2023 than it did in 2022.Click here to access BioCatch’s complete 2024 Digital Banking Fraud Trends in APAC report.
About BioCatch:BioCatch stands at the forefront of digital fraud detection, pioneering behavioral biometric intelligence grounded in advanced cognitive science and machine learning. BioCatch analyzes thousands of user interactions to support a digital banking environment where identity, trust, and ease coexist. Today, more than 30 of the world’s largest 100 banks and 196 total financial institutions rely on BioCatch Connect™ to combat fraud, facilitate digital transformation, and grow customer relationships. BioCatch’s Client Innovation Board – an industry-led initiative featuring American Express, Barclays, Citi Ventures, HSBC, and National Australia Bank – collaborates to pioneer creative and innovative ways to leverage customer relationships for fraud prevention. With more than a decade of data analysis, 92 registered patents, and unmatched expertise, BioCatch continues to lead innovation to address future challenges. For more information, please visit www.biocatch.com.
Media contact:Jay [email protected]
Logo – https://mma.prnewswire.com/media/1843699/biocatch_logo_rgb_2x_Logo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/more-than-150-000-money-laundering-accounts-detected-in-apac-302181474.html

Continue Reading

Artificial Intelligence

Puyi Fund, Managed by Highest Performances Holdings Inc., Surpasses RMB 24.0 Billion in Assets under Advice, Showing Promising Start to Strategic Transformation

Published

on

puyi-fund,-managed-by-highest-performances-holdings-inc,-surpasses-rmb-24.0-billion-in-assets-under-advice,-showing-promising-start-to-strategic-transformation

GUANGZHOU, China, June 25, 2024 /PRNewswire/ — Highest Performances Holdings Inc. (“HPH” or the Group, NASDAQ: HPH), announces that its Puyi Fund’s assets under advice for its asset allocation services reached RMB 24.7 billion as of June 21, 2024, reflecting a remarkable year-on-year growth of 188%. This substantial increase in scale showcases significant growth for the fund.

This accomplishment is primarily attributed to the Puyi Fund’s service philosophy, “long-term commitment to clients and clients’ long-term benefits,” introduced in 2023, as well as the ongoing efforts of the Company in adjusting its product strategy and embracing digital transformation. On one hand, the Company implemented a comprehensive family wealth management account system, redirecting its flagship products towards fixed-income funds and fund portfolios to enhance clients’ perception of wealth acquisition. On the other hand, the Company has elevated its overall service standard through digital transformation, greatly improving the client’s investment experience.
Transforming Product Strategy to Maximize Client Returns
In relation to product strategy transformation, Puyi Fund offers investors a comprehensive solution for managing their family wealth through a scientific approach. This solution guides investors in allocating their investment assets across three types of accounts: Flexible Withdrawal Accounts, Stable Appreciation Accounts, and High-Yield Pursuit Accounts. By considering various market conditions and cycles, investors can make informed decisions on how to distribute their funds among these accounts through a scientific approach for achieving risk mitigation, consistent asset growth, and long-term sustainable investment returns.
Taking into account the prevailing market conditions in China, Puyi Fund advises investors to allocate 25% to 90% of their funds to Stable Appreciation Accounts, depending on their risk tolerance. These accounts primarily involve investing in fixed-income funds, providing investors with consistent and reliable expected returns. By employing the stable appreciation strategy, Puyi Fund aims to restore investors’ confidence in the market, leading to increased trust and recognition. Consequently, Puyi Fund has experienced a period of rapid growth and positive development.
An analysis of data from the Chinese mutual fund market highlights the alignment of Puyi Fund’s client-centric product strategy transformation with market demands. According to Wind data, the market value of the Chinese mutual fund market stood at RMB 25.45 trillion at the end of 2021. By the end of May 2024, this amount grew to RMB 29.09 trillion, representing an increase of RMB 3.64 trillion or 14.30%. The value of equity and hybrid funds, however, experienced a decline from RMB 8.54 trillion to RMB 6.34 trillion, marking a decrease of RMB 2.21 trillion. In contrast, bond funds and money market funds collectively witnessed a significant increase of RMB 5.69 trillion. These market trends suggest that Chinese fund investors are shifting their risk preferences towards lower-risk and higher-certainty assets. Puyi Fund’s strategic transformation is well-positioned to take advantage of this evolving trend.
Enhancing Digital Service Innovation with a Focus on Client Service
In its digital transformation efforts, Puyi Fund places a strong emphasis on “client-centricity” and “service excellence”. By harnessing the power of big data, algorithm mining, and the Sensor Intelligent System, Puyi Fund establishes personalized service scenarios tailored to the unique needs of thousands of individuals. Through meticulous operations that cover the full client lifecycle, Puyi Fund offers full-scope online transactions for both public and private fund clients, establishing a distinctive digital competitive advantage. As of June 2024, the year-to-date client retention rate for fund advisory services stands at 75%, significantly enhancing the likelihood of investment profitability and returns for clients. This success enables clients to truly appreciate the value of advisory services and the time invested in their investments.
Furthermore, Puyi Fund has made continuous advancements in its intelligent client service system, leveraging digital platforms to offer investors comprehensive and efficient services. As of June 2024, the intelligent client service has catered to the needs of approximately 250,000 investors, providing 7*24 services, with a problem resolution rate surpassing 90%. Moreover, Puyi Fund complements intelligent client service with human support, resulting in a client satisfaction rate of 99%. This approach guarantees that investors receive timely and effective assistance whenever required.
Optimizing Trust-Based Communication Channels with Clients
Puyi Fund’s capability to swiftly establish client trust is attributable to its distinctive offline service channels. Unlike other third-party fund sales institutions that heavily rely on online platforms, Puyi Fund provides face-to-face, one-on-one services through offline channels. This approach is especially valuable in navigating complex investment environments, effectively calming investor emotions, enabling them to stay composed and gain a proper understanding of products, ultimately making well-informed investment decisions. Since 2024, Puyi Fund’s research and advisory team has released 28 specialized research reports and organized 19 online client exchanges, along with 35 offline client events, in response to market dynamics and client needs. These initiatives have effectively addressed investors’ concerns and enhanced their confidence.
It is worth mentioning that Puyi Fund’s institutional business has experienced remarkable growth this year, particularly in attracting clients from prominent financial institutions including banks, wealth management subsidiaries, and insurance companies. To cater specifically to institutional investors, Puyi Fund has developed an intelligent over-the-counter fund trading system called “Web-based Institution Master system”. This system provides institutional investors with a wide range of product portfolios, a comprehensive investment research system, and personalized trading experiences. As a result, it comprehensively improves the service quality and efficiency for institutional clients.
As of June 21, Puyi Fund established partnerships with 117 mutual fund companies, including the top 20 fund managers in terms of size, providing access to nearly 11,000 public funds and implementing over 20 customized advisory strategies. In the private fund sector, Puyi Fund has selected over 30 fund managers from the entire market. Of these, 38% manage assets over RMB 10 billion, while 29% manage assets between RMB 5 billion and RMB 10 billion. This selection covers a wide range of mainstream strategy products in the market, catering to the allocation needs of various types of investors.
It is reported that Puyi Fund, an independent third-party fund sales institution holding a fund sales business license issued by the China Securities Regulatory Commission, operates as a subsidiary of Highest Performances Holdings Inc. (NASDAQ: HPH). Embracing the concept of buyer advisor, Puyi Fund is dedicated to delivering comprehensive family financial asset allocation services to individual investors and diversified financial services to institutional investors through its financial technology service platform. With exceptional resource integration capabilities, professional research expertise, and high-quality client service, Puyi Fund strives to cultivate long-term partnerships with clients, catering to their personalized asset allocation needs in various scenarios while assisting a broader range of investors in achieving sustainable long-term returns. As of December 31, 2023, the accumulated assets under Puyi Fund’s allocation advisory services surpassed RMB 75.1 billion, exhibiting a compound annual growth rate of 128.8% from 2015 to 2023.
About Highest Performances Holdings Inc. (NASDAQ: HPH)
HPH was founded in 2010 with the aim of becoming a top provider of smart home and enterprise services. Its mission is to improve the quality of life for families worldwide, focusing on two main driving forces: “technological intelligence” and “capital investments.”HPH has a global strategic perspective and identifies high-quality enterprises with global potential for investment and operations. Its areas of focus include asset allocation, education and study tours, cultural tours, sports events, healthcare and elderly care and family governance.
HPH currently holds controlling interests in two leading financial service providers in China, namely Fanhua Inc., a technology-driven platform, and Fanhua Puyi Fund Distribution Co., Ltd., an independent wealth management service provider.
Highest Performances Holdings Inc., formerly known as Puyi Inc., was renamed on March 13, 2024 to reflect its strategic transformation.

View original content:https://www.prnewswire.co.uk/news-releases/puyi-fund-managed-by-highest-performances-holdings-inc-surpasses-rmb-24-0-billion-in-assets-under-advice-showing-promising-start-to-strategic-transformation-302181854.html

Continue Reading

Artificial Intelligence

ID Verify Now Available for Yardi Breeze Premier Clients

Published

on

id-verify-now-available-for-yardi-breeze-premier-clients

Leading software provider introduces biometric technology as the first step in the resident screening process
SANTA BARBARA, Calif.  , June 25, 2024 /PRNewswire/ — In response to the increase in fraudulent applications in multifamily rentals, Yardi® has launched ID Verify for Yardi Breeze® Premier clients in the United States and Canada. The use of biometrics is emerging as a standard screening practice in North America, as it allows property managers to confirm applicant identities before scheduling a tour.

Employing ID Verify as the initial step in the resident screening process provides Breeze Premier clients with a higher level of fraud prevention. Prospective renters simply upload a selfie and a photo of a government-issued identification document to the cloud. Then ID Verify detects fake IDs and validates real identities, ensuring a secure and reliable screening process. The new technology can also manage resident, visitor and vendor access, enhancing community security.
When paired with ScreeningWorks® Pro in the United States or Yardi® Resident Screening in Canada, property managers centralize resident screening data with their property data. This single source of truth provides multifamily businesses with a deeper understanding of who they’re renting to, ensuring greater confidence and quality in resident selection.
“Rising fraud increases the risks of bad debt,” said Peter Altobelli, vice president and general manager of Yardi Canada Ltd.” However, we’re optimistic that ID Verify will safeguard the future of the multifamily market when implemented as the first step in the resident screening process.”
Book a demo to learn more about ID Verify and how it will benefit your property management business.
About Yardi
Celebrating its 40-year anniversary in 2024, Yardi® develops industry-leading software for all types and sizes of real estate companies across the world. With over 9,000 employees, Yardi is working with our clients to drive significant innovation in the real estate industry. For more information on how Yardi is Energized for Tomorrow, visit yardi.com.
Photo – https://mma.prnewswire.com/media/2447765/Yardi_ID_Verify.jpgLogo – https://mma.prnewswire.com/media/737275/Yardi_Logo.jpg
 
 

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/id-verify-now-available-for-yardi-breeze-premier-clients-302181977.html

Continue Reading

Trending